Home › Multiple Myeloma › Washington › Seattle
Pag-aaral pangklinika para sa Multiple Myeloma sa Seattle, WA
Isang pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Seattle. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Nagre-recruitPhase 3
- Research Site, Seattle
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Nagre-recruitPhase 1/2
- University of Washington, Seattle
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Nagre-recruitPhase 2
- University of Washington, Seattle
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Nagre-recruitPhase 2
- Swedish Cancer Institute, Seattle
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Nagre-recruitPhase 3
- Fred Hutchinson Cancer Research Center, Seattle
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Nagre-recruitPhase 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Collection of Tissue Samples for Cancer Research
Nagre-recruitObservasyonal na pag-aaral
- Fred Hutchinson, Seattle
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 2
- Fred Hutchinson Cancer Center, Seattle
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Nagre-recruitPhase 3
- Saint Joseph Medical Center Hematology and Oncology - Silverdale, Silverdale · 17 mi ang layo
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Nagre-recruitPhase 1/2
- Research Site, Seattle
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Nagre-recruitPhase 3
- Research Site, Seattle
- Research Site, Seattle
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Nagre-recruitPhase 1/2
- Fred Hutch Cancer Center, Seattle
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Fred Hutchinson Cancer Center. /ID# 267940, Seattle
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Nagre-recruitPhase 1
- VA Puget Sound Health Care System, Seattle
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Nagre-recruitPhase 3
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- at 1 pa
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Fred Hutchinson Cancer Center, Seattle
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Swedish Medical Center - Seattle /ID# 268052, Seattle
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1/2
- Swedish Cancer Institute, Seattle
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Swedish Medical Center, Seattle
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
Nagre-recruit
- University of Washington, Seattle
Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
Nagre-recruit
- University of Washington, Seattle
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
Nagre-recruitObservasyonal na pag-aaral
- All4Cure, Seattle
Pag-aaral para sa Multiple Myeloma sa ibang lungsod
- New York City, NY60 pag-aaral
- Boston, MA42 pag-aaral
- Atlanta, GA41 pag-aaral
- Houston, TX38 pag-aaral
- Durham, NC37 pag-aaral
- Nashville, TN32 pag-aaral
- Denver, CO26 pag-aaral
- Columbus, OH24 pag-aaral
- Rochester, MN24 pag-aaral
- Baldwin Park, CA23 pag-aaral
- St. Louis, MO23 pag-aaral
- Washington, DC22 pag-aaral
Iba pang pag-aaral sa Seattle
- Non-Small Cell Lung Cancer53 pag-aaral
- Kanser (lahat ng uri)50 pag-aaral
- Kanser sa Prostate44 pag-aaral
- Acute Myeloid Leukemia40 pag-aaral
- Kanser sa Suso40 pag-aaral
- Metastatic Cancer39 pag-aaral
- Colorectal Cancer34 pag-aaral
- Kanser sa Baga33 pag-aaral
- Kanser sa Ovary31 pag-aaral
- Kanser sa Pancreas22 pag-aaral
- Acute Lymphoblastic Leukemia21 pag-aaral
- Myelodysplastic Syndromes21 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.